Clinical Transparency
Interactive Genetic Report Explorer
Explore sample diagnostic reports generated by our CLIA-certified partner laboratories, complete with clinical summaries and actionable physician guidance.
CLIA # 45D2109841 • CAP ACCREDITED
Clinical CompletePharmacogenomic (PGx) Precision Medication Profile
Patient: Harold M. • Age: 68 • Ordered by: Dr. Robert Vance, MD
Standard Therapeutic Response
Normal rate of metabolism. Use medication as typically directed.
Use with Caution / Monitor Dosage
Moderate gene-drug alteration. Physician may adjust baseline dosage.
High Risk / Consider Alternative
Severe toxicity or non-response risk. Alternative medication advised.
| Prescription Medication | Primary Indication | Associated Enzyme | Metabolic Phenotype | Actionable Clinical Recommendation |
|---|---|---|---|---|
| Clopidogrel (Plavix) | Cardiovascular / Antiplatelet | CYP2C19 | Intermediate Metabolizer (*1/*2) | Reduced bioactivation. Patient at increased risk for ischemic events. Consider alternative antiplatelet (e.g. Prasugrel or Ticagrelor). |
| Simvastatin (Zocor) | Hypercholesterolemia | SLCO1B1 | Decreased Function (*5) | Elevated systemic statin exposure. High risk of myopathy (muscle breakdown). Cap dose at 20mg or switch to Rosuvastatin. |
| Metoprolol (Lopressor) | Hypertension / Beta-Blocker | CYP2D6 | Normal Metabolizer (*1/*1) | Standard clearance rate observed. Initiate and titrate per standard clinical guidelines. |